Survival analysis of pleural malignant mesothelioma (MM) at a single Institution in Liguria, Italy Source: International Congress 2015 – Malignant pleural effusions and mesothelioma Year: 2015
Time to diagnosis and time to therapy in patients with malignant pleural mesothelioma (MPM) compared to patients with lung cancer in Denmark 2007 to 2011. A quality assurance analysis Source: Annual Congress 2012 - Biology and treatment of malignant pleural effusions Year: 2012
Prognostic factors and survival in malignant pleural mesothelioma at a large tertiary referral center in Turkey Source: Annual Congress 2012 - Clinical issues in malignant pleural effusions Year: 2012
Epidemiology, histology and thoracoscopic findings in malignant pleural mesothelioma (MPM) as second tumour in a single-centre cohort Source: Annual Congress 2010 - Clinical diagnosis and management of malignant pleural effusions Year: 2010
Malignant pleural mesothelioma (MPM) – 5 years of experience Source: Eur Respir J 2006; 28: Suppl. 50, 91s Year: 2006
Factors effecting malignant pleural mesothelioma incidence in rural part of Eskisehir, Turkey Source: Eur Respir J 2001; 18: Suppl. 33, 534s Year: 2001
Malignant pleural mesothelioma (MPM): clinical presentation, complications and survival Source: Eur Respir J 2002; 20: Suppl. 38, 272s Year: 2002
Malignant mesothelioma. A survival analysis of 123 consecutive cases at an occupational clinic Source: Annual Congress 2012 - Clinical issues in malignant pleural effusions Year: 2012
Cisplatin/pemetrexed chemotherapy versus palliative care survival in malignant pleural mesothelioma Source: International Congress 2018 – Clinical management of pleural malignancies, including mesothelioma Year: 2018
Salvage treatment in patients with recurrent or resistant malignant pleura mesothelioma. A retrospective study from tertiary oncology department Source: International Congress 2016 – Mesothelioma and malignant pleural disease Year: 2016
Malignant pleural mesothelioma (MPM) among workers exposed to asbestos in Santiago, Chile: frequency, characteristics and mortality Source: Annual Congress 2009 - Occupational exposures and disease I Year: 2009
Survival time in patients with malignant pleural mesothelioma Source: Annual Congress 2007 - Rare tumours, risk factors and epidemiology in thoracic oncology Year: 2007
Malignant pleural mesothelioma:a 16-year, single centre experience Source: International Congress 2017 – Pleural and mediastinal malignancies Year: 2017
Population-based survival for malignant mesothelioma after introduction of novel chemotherapy Source: Eur Respir J 2012; 40: 185-189 Year: 2012
A randomised trial of active symptom control (ASC) with or without chemotherapy (CT) in the treatment of patients with malignant pleural mesothelioma. First results of the Medical Research Council/British Thoracic Society MS01 trial Source: Annual Congress 2007 - Pleural malignancy Year: 2007
Malignant pleural mesothelioma: new treatment modalities Source: Annual Congress 2005 - Clinical year in review Year: 2005
Pleurectomy/decortication for malignant pleural mesothelioma: a single-centre experience. Source: Virtual Congress 2020 – Thoracic surgery: developments in diagnostics and outcomes Year: 2020
A 10-year experience of pleurodesis for malignant pleural effusion in a district general hospital Source: Annual Congress 2010 - Treatment of lung cancer Year: 2010
Pleurectomy, decortication and hyperthermic chemotheraphy in malignant pleural mesothelioma, a single institution experience Source: International Congress 2017 – General thoracic surgery Year: 2017
Is there any advantage of chemotherapy on survival of patients with diffuse malignant pleural mesothelioma? Source: Eur Respir J 2003; 22: Suppl. 45, 29s Year: 2003